MDA 2022 poster: Comparison of North Star Ambulatory Assessment score change in nmDMD patients receiving ataluren: STRIDE Registry vs Phase 3 clinical trial
This poster, from the 2022 MDA Conference in Nashville, Tennessee, USA, presents the ambulatory outcomes observed following treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD) in the STRIDE Registry and Study 020, a Phase 3 clinical trial
Read about the baseline demographics and characteristics of patients with nmDMD from the 2 study populations
Discover the results obtained from analysis of the STRIDE Registry of real-world data, compared with those of Study 020, a randomized, double-blind, placebo-controlled Phase 3 clinical trial
Learn about the changes in total and linear North Star Ambulatory Assessment (NSAA) scores and individual ambulatory function assessment items in both studies
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at firstname.lastname@example.org.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200045 I August 2023
Sign in or register to access exclusive content on this site